THX-150

Research and Development

THX-150: A Pharmaceutical Formulation of Cannabinoids with a Selected Antibacterial Agent for Infectious Diseases Caused by Multidrug Resistant (MDR) Bacteria

According to the World Health Organization, antimi­cro­bial resis­tance, classi­fied as a ‘serious threat’, occurs when microor­gan­isms are exposed to antimi­cro­bial drugs. As a result, medicines become ineffec­tive and infec­tions persist, increasing the risk of spread. Antimicrobial resis­tance increases the cost of health­care with lengthier stays in hospi­tals and more inten­sive care required.

According to the U.S. Centers for Disease Control and Prevention, antibiotic-resistant infec­tions add consid­er­able costs to the U.S. health­care system. In most cases, antibiotic-resistant infec­tions require prolonged and/or costlier treat­ments, extend hospital stays, neces­si­tate additional doctor visits and health­care use, and result in greater disability and death compared with infec­tions that are easily treat­able with antibi­otics.

THX-150 is a drug candi­date intended for the treat­ment of infec­tious diseases. It is a pharma­ceu­tical formu­la­tion of cannabi­noids with a selected antibac­te­rial agent and possesses antimi­cro­bial synergy poten­tial. Antibiotics are a type of antimi­cro­bial drug used in the treat­ment and preven­tion of bacte­rial infec­tion.